Skip to main content

Table 1 Population characteristics of TVD patients who received follow-up CAG after second-generation DES implantation

From: Risk factors for revascularization and in-stent restenosis in patients with triple-vessel disease after second-generation drug-eluting stent implantation: a retrospective analysis

Population characteristics TVD patients (n = 246) Revascularization group (n = 142) Nonrevascularization group (n = 104) P value ISR group (n = 43) Non-ISR group (n = 203) p value
Age (years) 64.3 ± 10.0 63.8 ± 9.9 65.0 ± 10.0 0.340 67.3 ± 10.2 63.6 ± 9.8 0.029•
Male (n, %) 174 (70.7%) 101 (71.1%) 73 (70.2%) 0.874 31 (72.1%) 143 (70.4%) 0.829
BMI (kg/m2) 26.2 ± 3.3 26.2 ± 3.4 26.2 ± 3.2 0.948 26.1 ± 2.9 26.2 ± 3.3 0.858
Current smoking (n, %) 92 (37.4%) 66 (46.5%) 26 (25.0%) 0.001* 22 (51.2%) 70 (34.5%) 0.040•
Current alcohol intake (n, %) 66 (26.8%) 41 (28.9%) 25 (24.0%) 0.398 10 (23.3%) 56 (27.6%) 0.560
Hypertension (n, %) 186 (75.6%) 112 (78.9%) 74 (71.2%) 0.164 32 (74.4%) 154 (75.9%) 0.841
SBP > 140 and/or DBP > 90 (n, %) 70 (29.3%) 38 (26.8%) 34 (32.4%) 0.312 10 (23.3%) 62 (30.5%) 0.340
Diabetes (n, %) 129 (52.4%) 81 (57.0%) 48 (46.2%) 0.091 24 (55.8%) 105 (51.7%) 0.626
Family history of CAD (n, %) 76 (30.9%) 45 (31.7%) 31 (29.8%) 0.752 12 (27.9%) 64 (31.5%) 0.641
CKD1-3 (n, %) 20 (8.1%) 13 (9.2%) 7 (6.7%) 0.492 5 (11.6%) 15 (7.4%) 0.356
CKD4-5 (n, %) 9 (3.7%) 9 (6.3%) 0 / 4 (9.3%) 5 (2.5%) 0.030•
Angina pectoris or precordial distress (n, %) 202 (82.1%) 136 (95.8%) 66 (63.5%)  < 0.001* 38 (88.4%) 164 (80.8%) 0.238
Laboratory test
TC (mmol/L) 3.63 ± 0.84 3.76 ± 0.90 3.44 ± 0.74 0.005* 3.84 ± 1.04 3.58 ± 0.79 0.073
LDL-C (mmol/L) 1.95 ± 0.63 2.07 ± 0.69 1.79 ± 0.51 0.001* 2.00 ± 0.75 1.94 ± 0.61 0.552
HDL-C (mmol/L) 1.00 ± 0.24 0.97 ± 0.22 1.05 ± 0.26 0.004* 1.01 ± 0.30 0.99 ± 0.23 0.674
Non-HDL-C (mmol/L) 2.63 ± 0.81 2.80 ± 0.75 2.40 ± 0.66  < 0.001* 2.83 ± 1.05 2.59 ± 0.75 0.083
ApoB (g/L) 0.74 ± 0.20 0.77 ± 0.20 0.70 ± 0.18 0.009* 0.74 ± 0.19 0.74 ± 0.20 0.788
NEU (× 109) 4.39 ± 1.40 4.59 ± 1.48 4.11 ± 1.23 0.008* 4.72 ± 1.46 4.31 ± 1.38 0.078
LY (× 109) 1.82 ± 0.69 1.80 ± 0.66 1.82 ± 0.73 0.874 1.80 ± 0.65 1.81 ± 0.70 0.923
NLR 2.40 (1.88, 3.08) 2.43 (1.91, 3.29) 2.26 (1.81, 2.86) 0.120 2.50 (2.11, 3.58) 2.39 (1.86, 3.05) 0.179
WBC (× 109) 6.82 ± 1.82 7.04 ± 1.83 6.52 ± 1.79 0.672 7.15 ± 1.95 6.74 ± 1.80 0.184
Hs-CRP (mg/L) 0.96 (0.43, 2.22) 1.22 (0.53, 2.68) 0.83 (0.39, 1.88) 0.022* 1.38 (0.70, 3.23) 0.92 (0.40, 2.15) 0.066
HbA1c (%) 6.3 (5.8, 7.3) 6.4 (5.8, 7.8) 6.2 (5.8, 6.8) 0.090 6.4 (6.0, 8.4) 6.2 (5.8, 7.1) 0.050
SUA (μmol/L) 351 (296, 403) 357(297, 409) 339 ± 78 0.320 341 (289, 401) 354 (299, 405) 0.680
Previous findings
ACS (n/%) 154 (62.6%) 88 (62.0%) 66 (63.5) 0.811 19 (44.2%) 73 (36.0%) 0.311
Target vessel at LM (n/%) 22 (8.9%) 9 (5.3%) 13 (12.5%) 0.094 2 (4.7%) 20 (9.9%) 0.278
Target vessel at LAD only (n/%) 63 (25.6%) 36 (25.4%) 27 (26.0%) 0.914 14 (32.6%) 49 (24.1%) 0.250
Target vessel at LCX only (n/%) 29 (11.8%) 18 (12.7%) 11(10.6%) 0.614 0 (0%) 29 (4.3%) /
Target vessel at RCA only (n/%) 45 (18.3%) 26 (18.3%) 19 (18.3%) 0.994 6 (14.0%) 39 (19.2%) 0.418
Two vessels stenting (n/%) 93 (37.8%) 53 (37.3%) 40 (38.5%) 0.856 18 (41.9%) 75 (36.9%) 0.546
Triple vessels stenting (n/%) 17 (6.9%) 10 (7.0%) 7 (6.7%) 0.924 5 (11.6%) 12 (5.9%) 0.179
SYNTAX score 12.9 ± 4.5 13.4 ± 4.7 12.4 ± 4.0 0.085 12.6 ± 5.3 13.0 ± 4.3 0.558
Everolimus/zotarolimus-eluting stents (n/%) 184 (74.8%) 107 (75.4%) 77 (74.0%) 0.815 31 (72.3%) 153 (75.4%) 0.653
Time of follow-up (months) 28.0 (14.0,56.0) 16.8 (38.0,63.0) 23.5 (13.0,48.5) 0.002* 39.0 (22.0,78.0) 27.0 (14.0, 53.0) 0.024•
  1. Data are presented as the mean ± SD, median (interquartile range) and (n/%)
  2. TVD triple-vessel disease, CAG coronary angiography, DES drug-eluting stents, ISR in-stent restenosis, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, CAD coronary artery disease, CKD chronic kidney disease, TC total cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, non-HDL-C non-high-density lipoprotein cholesterol, ApoB apolipoprotein B, NEU neutrophil, LY lymphocyte, NLR neutrophil-to-lymphocyte ratio, WBC white blood cell, Hs-CRP high-sensitivity C-reactive protein, HbA1c glycosylated hemoglobin A1c, HCY homocysteine, SUA serum uric acid, LM left main coronary artery disease, LAD left anterior descending branch, LCX left circumflex artery RCA, right coronary artery
  3. *P < 0.05, compared with nonrevascularization cases; •P < 0.05, compared with non-ISR cases